Piramal Pharma (PPLPHARMA) Investor Presentation summary

Company overview and strategic priorities

• Aims to become a US $2+ billion global pharma, health, and wellness company by FY2030, targeting top 10 in addressable markets.

• Operates across CDMO, Complex Hospital Generics (CHG), India Consumer Healthcare (ICH), and a joint venture with Abbvie.

• 70% of revenue comes from regulated markets, with a diversified global footprint and customer base.

• Strong focus on sustainability, with SBTi-approved GHG reduction targets and robust governance.

• Board comprises experienced leaders, with 50% independent directors and a strong quality compliance record.

Financial aspirations and growth strategy

• Targets over 3x EBITDA growth and more than double revenues by FY2030, aiming for ~25% EBITDA margins.

• Plans to reduce leverage to ~1x net debt/EBITDA and achieve high teens ROCE.

• Growth driven by organic and inorganic expansion, focusing on differentiated capabilities and synergies.

• Strategic investments will be guided by financial performance, debt levels, and cash flows.

• Key risks include macroeconomic challenges, supply chain disruptions, and pipeline attrition, with mitigation plans in place.

CDMO business highlights

• Integrated CDMO with global operations, offering services across the molecule lifecycle and 150+ projects in development.

• Over 50% of CDMO revenue from innovation-related work, with increasing contribution from differentiated offerings.

• Network of facilities in India, North America, and Europe enables cross-sell and supply chain flexibility.

• Customer base is diversified, with 64% of revenue from Big Pharma and emerging biopharma, and 84% from regulated markets.

• Strategic goal to reach US $1.2 billion in CDMO revenue with ~25% EBITDA margin by FY2030.